Several headwinds have pushed Regeneron 's (NASDAQ: REGN) shares lower over the past year and a half. However, the company is bouncing back and has performed well in recent months. What's more, there ...

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene writing program, inking a deal that lets it in on a ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

With T-cell engagers already established as late-line therapies for certain blood cancers, Regeneron has released early data ...

Regeneron Pharmaceuticals earns the No. 76 rank among its peers in the Medical-Biomed/Biotech industry group. Exact Sciences ...

The company's BCMAxCD3 bispecific antibody Lynozyfic (linvoseltamab) got its first FDA approval as a fifth-line or later ...

Regeneron released new early data on two of its blood cancer drugs at ASH, aiming to expand treatment options for patients ...

Regeneron said on Saturday its experimental cancer combination therapy was effective and showed disappearance of the disease ...

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing ...

The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a ...